1
|
Chour A, Denis J, Mascaux C, Zysman M, Bigay-Game L, Swalduz A, Gounant V, Cortot A, Darrason M, Fallet V, Auclin E, Basse C, Tissot C, Decroisette C, Bombaron P, Giroux-Leprieur E, Odier L, Brosseau S, Creusot Q, Gueçamburu M, Meersseman C, Rochand A, Costantini A, Gaillard CM, Wasielewski E, Girard N, Cadranel J, Lafitte C, Lebossé F, Duruisseaux M. Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRAS G12C-Mutant Lung Cancer. J Thorac Oncol 2023; 18:1408-1415. [PMID: 37217096 DOI: 10.1016/j.jtho.2023.05.013] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2023] [Revised: 04/28/2023] [Accepted: 05/15/2023] [Indexed: 05/24/2023]
Abstract
INTRODUCTION Sequential anti-programmed cell death protein 1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) followed by small targeted therapy use is associated with increased prevalence of adverse events (AEs) in NSCLC. KRASG12C inhibitor sotorasib may trigger severe immune-mediated hepatotoxicity when used in sequence or in combination with anti-PD-(L)1. This study was designed to address whether sequential anti-PD-(L)1 and sotorasib therapy increases the risk of hepatotoxicity and other AEs. METHODS This is a multicenter, retrospective study of consecutive advanced KRASG12C-mutant NSCLC treated with sotorasib outside clinical trials in 16 French medical centers. Patient records were reviewed to identify sotorasib-related AEs (National Cancer Institute Common Classification Criteria for Adverse Events-Version 5.0). Grade 3 and higher AE was considered as severe. Sequence group was defined as patients who received an anti-PD-(L)1 as last line of treatment before sotorasib initiation and control group as patients who did not receive an anti-PD-(L)1 as last line of treatment before sotorasib initiation. RESULTS We identified 102 patients who received sotorasib, including 48 (47%) in the sequence group and 54 (53%) in the control group. Patients in the control group received an anti-PD-(L)1 followed by at least one treatment regimen before sotorasib in 87% of the cases or did not receive an anti-PD-(L)1 at any time before sotorasib in 13% of the cases. Severe sotorasib-related AEs were significantly more frequent in the sequence group compared with those in the control group (50% versus 13%, p < 0.001). Severe sotorasib-related AEs occurred in 24 patients (24 of 48, 50%) in the sequence group, and among them 16 (67%) experienced a severe sotorasib-related hepatotoxicity. Severe sotorasib-related hepatotoxicity was threefold more frequent in the sequence group compared with that in the control group (33% versus 11%, p = 0.006). No fatal sotorasib-related hepatotoxicity was reported. Non-liver severe sotorasib-related AEs were significantly more frequent in the sequence group (27% versus 4%, p < 0.001). Severe sotorasib-related AEs typically occurred in patients who received last anti-PD-(L)1 infusion within 30 days before sotorasib initiation. CONCLUSIONS Sequential anti-PD-(L)1 and sotorasib therapy are associated with a significantly increased risk of severe sotorasib-related hepatotoxicity and severe non-liver AEs. We suggest avoiding starting sotorasib within 30 days from the last anti-PD-(L)1 infusion.
Collapse
Affiliation(s)
- Ali Chour
- Respiratory Department and Early Phase, Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute, Lyon, France; Oncopharmacology Laboratory, Cancer Research Center of Lyon, Unité mixte de recherche (UMR) Institut national de la santé et de la recherche médicale (INSERM) 1052 Centre national de la recherche scientifique (CNRS) 5286, Lyon, France; Université Claude Bernard, Université de Lyon, Lyon, France
| | - Julie Denis
- Respiratory Department and Early Phase, Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute, Lyon, France; Université Claude Bernard, Université de Lyon, Lyon, France
| | - Céline Mascaux
- Pulmonology Department, University Hospital of Strasbourg, Strasbourg, France; Université de Strasbourg, Institut national de la santé et de la recherche médicale (INSERM) Unité mixte de recherche (UMR)_S 1113, IRFAC, Laboratory Streinth (Stress REsponse and INnovative THerapy against cancer), ITI InnoVec, Strasbourg, France
| | - Maeva Zysman
- Service des Maladies Respiratoires et des épreuves fonctionnelles respiratoires CHU Bordeaux, Pessac, France; Univ-Bordeaux, Centre de Recherche cardio-thoracique de Bordeaux, U1045, CIC 1401.-F, Pessac, France
| | | | | | - Valérie Gounant
- Thoracic Oncology Department-Early Phases Unit CIC-1425 Institut national de la santé et de la recherche médicale (INSERM), Institut du cancer Assistance Publique-Hôpitaux de Paris (AP-HP) Nord, Hôpital Bichat-Claude Bernard, Paris, France; Université Paris Cité, Paris, France
| | - Alexis Cortot
- Thoracic Oncology Department, Centre Hospitalier Régional Universitaire de Lille, Lille, France
| | - Marie Darrason
- Service de Pneumologie, Lyon Sud Hospital Center, Pierre-Benite, France
| | - Vincent Fallet
- Hopital Tenon Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; GRC 4, Theranoscan, Sorbonne Université, Paris, France
| | - Edouard Auclin
- Oncology Department, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP) centre, Université Paris Cité, Paris, France
| | - Clémence Basse
- Thorax Institute Curie Montsouris, Institut Curie, Paris, France; UVSQ, Paris Saclay University, Versailles, France
| | - Claire Tissot
- Institut de Cancérologie de la Loire, Saint-Priest-en-Jarez, France
| | | | | | - Etienne Giroux-Leprieur
- Respiratory Diseases and Thoracic Oncology Department, Hôpital Ambroise Pare Assistance Publique-Hôpitaux de Paris (AP-HP), Boulogne-Billancourt, France
| | - Luc Odier
- Department of Pneumology, Hopital Nord-Ouest Villefranche, Villefranche Sur Saone, France
| | - Solenn Brosseau
- Thoracic Oncology Department-Early Phases Unit CIC-1425 Institut national de la santé et de la recherche médicale (INSERM), Institut du cancer Assistance Publique-Hôpitaux de Paris (AP-HP) Nord, Hôpital Bichat-Claude Bernard, Paris, France; Université Paris Cité, Paris, France
| | - Quentin Creusot
- Pulmonology Department, University Hospital of Strasbourg, Strasbourg, France; Université de Strasbourg, Institut national de la santé et de la recherche médicale (INSERM) Unité mixte de recherche (UMR)_S 1113, IRFAC, Laboratory Streinth (Stress REsponse and INnovative THerapy against cancer), ITI InnoVec, Strasbourg, France
| | - Marina Gueçamburu
- Service des Maladies Respiratoires et des épreuves fonctionnelles respiratoires CHU Bordeaux, Pessac, France; Univ-Bordeaux, Centre de Recherche cardio-thoracique de Bordeaux, U1045, CIC 1401.-F, Pessac, France
| | | | - Adrien Rochand
- Oncology Department, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP) centre, Université Paris Cité, Paris, France
| | - Adrien Costantini
- Respiratory Diseases and Thoracic Oncology Department, Hôpital Ambroise Pare Assistance Publique-Hôpitaux de Paris (AP-HP), Boulogne-Billancourt, France
| | - Claire Marine Gaillard
- Department of Pneumology, Hopital Nord-Ouest Villefranche, Villefranche Sur Saone, France
| | - Eric Wasielewski
- Thoracic Oncology Department, Centre Hospitalier Régional Universitaire de Lille, Lille, France
| | - Nicolas Girard
- Thorax Institute Curie Montsouris, Institut Curie, Paris, France; UVSQ, Paris Saclay University, Versailles, France
| | - Jacques Cadranel
- Hopital Tenon Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Claire Lafitte
- Respiratory Department and Early Phase, Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute, Lyon, France
| | - Fanny Lebossé
- Hepatology unit, Croix Rousse hospital, Lyon Liver Institute, Hospices Civils of Lyon, Lyon, France; Cancer Research Center of Lyon, Unité mixte de recherche (UMR) Institut national de la santé et de la recherche médicale (INSERM) 1052 Centre national de la recherche scientifique (CNRS) 5286, Lyon, France
| | - Michaël Duruisseaux
- Respiratory Department and Early Phase, Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute, Lyon, France; Oncopharmacology Laboratory, Cancer Research Center of Lyon, Unité mixte de recherche (UMR) Institut national de la santé et de la recherche médicale (INSERM) 1052 Centre national de la recherche scientifique (CNRS) 5286, Lyon, France; Université Claude Bernard, Université de Lyon, Lyon, France.
| |
Collapse
|
2
|
Chour A, Denis J, Lafitte C, Mascaux C, Zysman M, Lemaitre A, Swalduz A, Gounant V, Cortot A, Darrason M, Cadranel J, Auclin E, Basse C, Tissot C, Decroisette C, Bombaron P, Giroux-Leprieur E, Falchero L, Lebossé F, Duruisseaux M. 37P Sotorasib-induced liver and non-liver toxicity associated with sequential sotorasib following anti-PD(L)1 in KRASG12C mutant lung cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
3
|
Barlesi F, Dixmier A, Debieuvre D, Raspaud C, Auliac J, Nicolas B, Bombaron P, Moro-Sibilot D, Audigier-Valette C, Asselain B, Dumanoir J, Cotté FE, Allan V, Calvet C, Reynaud D, Pérol M. 1348P Long-term survival and health-related quality of life with nivolumab for previously-treated advanced non-small cell lung cancer (NSCLC): A wide prospective French real-world study (EVIDENS). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1949] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
4
|
Debieuvre D, Juergens RA, Asselain B, Audigier-Valette C, Auliac JB, Barlesi F, Benoit N, Bombaron P, Butts CA, Dixmier A, Gröschel A, Gutz S, Labbé C, Moro-Sibilot D, Pérol M, Raspaud C, Schumann C, Juarez-Garcia A, Lakhdari K, Pettersson F, Penrod JR, Reynaud D, Waldenberger D, Allan V, Sebastian M. Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada. Lung Cancer 2021; 157:40-47. [PMID: 33980420 DOI: 10.1016/j.lungcan.2021.04.022] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2021] [Revised: 04/23/2021] [Accepted: 04/25/2021] [Indexed: 11/25/2022]
Abstract
OBJECTIVES Immune checkpoint inhibitors have become the standard of care for metastatic non-small-cell lung cancer (NSCLC) progressing during or after platinum-based chemotherapy. Real-world clinical practice tends to represent more diverse patient characteristics than randomized clinical trials. We sought to evaluate overall survival (OS) outcomes in the total study population and in key subsets of patients who received nivolumab for previously treated advanced NSCLC in real-world settings in France, Germany, or Canada. MATERIALS AND METHODS Data were pooled from two prospective observational cohort studies, EVIDENS and ENLARGE, and a retrospective registry in Canada. Patients included in this analysis were aged ≥18 years, had stage IIIB/IV NSCLC, and received nivolumab after at least one prior line of systemic therapy. OS was estimated in the pooled population and in various subgroups using the Kaplan-Meier method. Timing of data collection varied across cohorts (2015-2019). RESULTS Of the 2585 patients included in this analyses, 1235 (47.8 %) were treated in France, 881 (34.1 %) in Germany, and 469 (18.1 %) in Canada. Median OS for the total study population was 11.3 months (95 % CI: 10.5-12.2); this was similar across France, Germany, and Canada. The OS rate was 49 % at 1 year and 28 % at 2 years for the total study population. In univariable Cox analyses, the presence of epidermal growth factor receptor mutations in nonsquamous disease, liver, or bone metastases were associated with significantly shorter OS, whereas tumor programmed death ligand 1 expression and Eastern Cooperative Oncology Group performance status 0-1 were associated with significantly prolonged OS. Similar OS was noted across subgroups of age and prior lines of therapy. CONCLUSION OS rates in patients receiving nivolumab for previously treated advanced NSCLC in real-world clinical practice closely mirrored those in phase 3 studies, suggesting similar effectiveness of nivolumab in clinical trials and clinical practice.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Sylvia Gutz
- Ev. Diakonissenkrankenhaus, Leipzig, Germany
| | - Catherine Labbé
- Institut universitaire de cardiologie et de pneumologie de Québec, Quebec City, QC, Canada
| | - Denis Moro-Sibilot
- Thoracic Oncology Unit, SHUPP, Centre Hospitalier Universitaire Grenoble-Alpes, Grenoble, France
| | | | | | - Christian Schumann
- Klinikverbund Allgäu, Klinik für Pneumologie, Thoraxonkologie, Schlaf- und Beatmungsmedizin, Kempten Und Immenstadt, Germany
| | | | | | | | | | | | | | | | - Martin Sebastian
- University Hospital, Goethe-University Frankfurt, Department of Hematology and Medical Oncology, Frankfurt, Germany.
| |
Collapse
|
5
|
Barlesi F, Dixmier A, Debieuvre D, Raspaud C, Auliac J, Benoit N, Bombaron P, Moro-Sibilot D, Audigier-Valette C, Asselain B, Dumanoir J, Cotte FE, Allan V, Ozan N, Calvet C, Reynaud D, Pérol M. 1325P Long-term survival and health-related quality of life in patients treated with nivolumab for advanced non-small cell lung cancer: A wide prospective French real-world study (EVIDENS). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
6
|
Barlesi F, Dixmier A, Debieuvre D, Raspaud C, Auliac JB, Benoit N, Bombaron P, Moro-Sibilot D, Audigier-Valette C, Asselain B, Egenod T, Rabeau A, Fayette J, Sanchez ML, Labourey JL, Westeel V, Lamoureux P, Cotte FE, Allan V, Daumont M, Dumanoir J, Reynaud D, Calvet CY, Ozan N, Pérol M. Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study. Oncoimmunology 2020; 9:1744898. [PMID: 33457089 PMCID: PMC7790497 DOI: 10.1080/2162402x.2020.1744898] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
EVIDENS is an ongoing, prospective, non-interventional study evaluating the effectiveness and safety of nivolumab in lung cancer patients in France (ClinicalTrials.gov NCT03382496). Adults with a pathologically confirmed diagnosis of lung cancer and initiating treatment with nivolumab were recruited from 146 sites in France. This analysis included only patients with non-small cell lung cancer (NSCLC) who received ≥1 nivolumab infusion, and evaluated patient characteristics at the time of nivolumab initiation and its effectiveness and safety after a median follow-up of 18 months. A total of 1,420 patients with NSCLC were included, most of whom had an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0–1 (82.9%), non-squamous histology (69.2%) and stage IV disease (91.4%). Brain metastases were present in 19.9% of patients. Nivolumab was a second-line or ≥third-line regimen in 73.6% and 26.1% of patients, respectively. Almost all patients had prior chemotherapy (99.7%). Median overall survival was 11.2 months (95% confidence interval [CI]: 10.0–12.4). ECOG PS, smoking status, corticosteroids at baseline, epidermal growth factor receptor mutation status, presence of symptomatic brain metastases and treatment-related adverse events (TRAEs) were independent predictors of survival. Grade 3 and 4 TRAEs were reported in 105 (7.4%) and 12 (0.8%) patients, respectively; no treatment-related deaths were reported. Preliminary results of the EVIDENS study confirm the effectiveness and safety of nivolumab, mostly in pre-treated advanced NSCLC patients, with similar benefits to those observed in the phase III randomized clinical trials, despite a broader study population.
Collapse
Affiliation(s)
- Fabrice Barlesi
- CNRS, INSERM, CRCM, Assistance Publique Hôpitaux de Marseille, Hopital Nord, Pavillon Mistral, 6ème Étage A, Chemin des Bourrely, Aix Marseille University, Marseille, France
| | - Adrien Dixmier
- Department of Pulmonology, Centre Hospitalier Régional d'Orléans, Orléans, France
| | - Didier Debieuvre
- Respiratory Medicine Department, Groupe Hospitalier De La Région Mulhouse Sud-Alsace, Hopital Emile Muller, Mulhouse, France
| | | | - Jean-Bernard Auliac
- Department of Pulmonology, Centre Hospitalier Intercommunal de Créteil, Créteil, France
| | - Nicolas Benoit
- Department of Pulmonology, Clinique de l'Europe, Amiens, France
| | - Pierre Bombaron
- Department of Pulmonology, Hôpital Privé Jean Mermoz, Lyon, France
| | - Denis Moro-Sibilot
- Thoracic Oncology Unit, SHUPP, Centre Hospitalier Universitaire Grenoble-Alpes, Grenoble Cedex, France
| | | | | | - Thomas Egenod
- Department of Cutaneous and Thoracic Oncology, Centre Hospitalier Universitaire Dupuytren, Limoges, France
| | - Audrey Rabeau
- Thoracic Oncology Department, Centre Hospitalier Universitaire de Toulouse, Hopital Rangueil, Toulouse, France
| | - Jérôme Fayette
- Department of Medicine, Centre Léon Bérard, Lyon, France
| | - Myriam Locatelli Sanchez
- Department of Thoracic Oncology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Lyon, France
| | | | - Virginie Westeel
- Chest Disease Department, University Hospital, INSERM UMR 1098, University of Bourgogne Franche-Comté, Besançon, France
| | | | | | | | | | | | | | | | | | - Maurice Pérol
- Department of Medical Oncology, Centre Léon Bérard, Lyon, France
| |
Collapse
|
7
|
Barlesi F, Dixmier A, Debieuvre D, Raspaud C, Auliac J, Benoit N, Bombaron P, Moro-Sibilot D, Audigier-Valette C, Asselain B, Lamoureux P, Cotté FE, Allan V, Daumont M, Ozan N, Calvet C, Perol M. Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: Updated survival and subgroup analysis from the real-world EVIDENS study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.016] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
Swalduz A, Souquet PJ, Pérol M, Moro-Sibilot D, Schiffler C, Chabaud S, Fayet Y, Rogasik M, Labrosse H, Farsi F, Brun P, Decroisette C, Bombaron P, Bringuier PP, Haddad V, Forest F, Peoc’h M, Lantuejoul S, de Fraipont F, Ray-Coquard I, Fournel P. Compliance to regional recommendations for molecular analyses and management of advanced lung cancer patients. Future Oncol 2019; 15:2139-2149. [DOI: 10.2217/fon-2018-0943] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Aim: We performed a clinical audit of the management of patients with EGFR mutations, 1 year after the introduction of EGFR tyrosine kinase inhibitor ( EGFR-TKI) in first-line treatment. Methods: Compliance was defined by tumor molecular profiling for stage IIIB and IV non-small-cell lung cancer and first-line treatment as recommended by the French guidelines. Results: Among the 169 EGFR-mutated patients, compliance was 76.4%. The most common noncompliance criterion was chemotherapy given in first-line treatment instead of EGFR-TKI. No dedicated multidisciplinary meeting and type of institutions were independent unfavorable predictors for compliance. Compliance to guidelines was significantly correlated with time-to-first subsequent treatment improvement (2.5 vs 9.1 months; p < 0.0001). Conclusion: Implementation of new standards of care is challenging. Our results reinforce the role of multidisciplinary meetings to provide a better access to innovating therapeutics.
Collapse
Affiliation(s)
- Aurélie Swalduz
- Department of Chest Diseases & Thoracic Oncology, University Hospital of Saint-Étienne, 42270, Saint Priest en Jarez, France
- Department of Medicine, Centre Léon Bérard, 69008, Lyon, France
| | - Pierre-Jean Souquet
- Department of Respiratory Medicine, Lyon Sud Hospital, Hospices Civils de Lyon, 69310 Pierre-Bénite, France
| | - Maurice Pérol
- Department of Medicine, Centre Léon Bérard, 69008, Lyon, France
| | - Denis Moro-Sibilot
- Pulmonology & Thoracic Oncology Department, Grenoble University Hospital, 38700, Grenoble, France
- Medicine Faculty, Joseph Fourrier University, 38043, La Tronche, France
| | - Camille Schiffler
- Department of Biostatistics, Centre Léon Bérard, 69008, Lyon, France
| | - Sylvie Chabaud
- Department of Biostatistics, Centre Léon Bérard, 69008, Lyon, France
| | - Yohan Fayet
- Équipe Évaluation Médicales et Sarcome (EMS), Centre Léon Bérard, 69008 Lyon, France
| | - Muriel Rogasik
- Équipe Évaluation Médicales et Sarcome (EMS), Centre Léon Bérard, 69008 Lyon, France
| | | | - Fadila Farsi
- Réseau Espace Santé Cancer Rhône-Alpes, 69008, Lyon, France
| | - Philippe Brun
- Department of Respiratory Medicine, Valence Hospital, 26953, Valence, France
| | - Chantal Decroisette
- Department of Respiratory Medicine, Annecy Genevois Hospital, 74370, Metz-Tessy, France
| | - Pierre Bombaron
- Department of Respiratory Medicine, Mermoz Private Hospital, 69008, Lyon, France
| | - Pierre-Paul Bringuier
- Molecular Diagnostics Laboratory, Edouard-Herriot Hospital, Hospices Civils de Lyon, 69003, Lyon, France
| | - Véronique Haddad
- Department of Biopathology, Centre Léon Bérard, 69008, Lyon, France
| | - Fabien Forest
- Department of Pathology, University Hospital of Saint Étienne, 42270, Saint Priest en Jarez, France
| | - Michel Peoc’h
- Department of Pathology, University Hospital of Saint Étienne, 42270, Saint Priest en Jarez, France
| | - Sylvie Lantuejoul
- Medicine Faculty, Joseph Fourrier University, 38043, La Tronche, France
- Department of Biopathology, Centre Léon Bérard, 69008, Lyon, France
| | - Florence de Fraipont
- Institue of Biology & Pathology, Grenoble University Hospital, 38043, Grenoble, France
| | - Isabelle Ray-Coquard
- Department of Medicine, Centre Léon Bérard, 69008, Lyon, France
- Université Claude Bernard Lyon 1, 69008, Lyon, France
| | - Pierre Fournel
- Department of Medical Oncology, Institut Lucien Neuwirth, 42270, Saint-Priest-en-Jarez, France
| |
Collapse
|
9
|
Pérol M, Dixmier A, Barlesi F, Debieuvre D, Raspaud C, Auliac J, Benoit N, Bombaron P, Moro-Sibilot D, Asselain B, Cotté FE, Lamoureux P, Karam N, Ozan N, Calvet C, Bryan B, Allan V, Audigier Valette C. Health-related quality of life (HRQoL) of non-small cell lung cancer (NSCLC) patients treated with nivolumab in real-life: The EVIDENS study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz063.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
10
|
Dixmier A, Debieuvre D, Raspaud C, Auliac J, Benoit N, Bombaron P, Asselain B, Calvet C, Lamoureux P, Goyard N, Moro-Sibilot D, Pérol M, Barlesi F, Audigier-Valette C. Résultats de l’analyse intermédiaire de l’étude EVIDENS : patients atteints de cancer bronchopulmonaire traités par nivolumab en condition de vie réelle en France. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
11
|
Dixmier A, Debieuvre D, Raspaud C, Auliac J, Benoit N, Bombaron P, Asselain B, Dumont A, Lamoureux P, Goyard N, Moro-Sibilot D, Perol M, Barlesi F, Audigier Valette C. EVIDENS: An observational study of nivolumab-treated patients in advanced non-small cell lung cancer (NSCLC) in a real-world setting: Initial results on 1394 patients. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
12
|
Moran T, Wei J, Cobo M, Qian X, Domine M, Zou Z, Bover I, Wang L, Provencio M, Yu L, Chaib I, You C, Massuti B, Song Y, Vergnenegre A, Lu H, Lopez-Vivanco G, Hu W, Robinet G, Yan J, Insa A, Xu X, Majem M, Chen X, de Las Peñas R, Karachaliou N, Sala MA, Wu Q, Isla D, Zhou Y, Baize N, Zhang F, Garde J, Germonpre P, Rauh S, ALHusaini H, Sanchez-Ronco M, Drozdowskyj A, Sanchez JJ, Camps C, Liu B, Rosell R, Colinet B, De Grève J, Germonpré P, Chen H, Chen X, Du J, Gao Y, Hu J, Hu W, Kong W, Li L, Li R, Li X, Liu B, Liu J, Lu H, Qian X, Ren W, Song Y, Wang L, Wei J, Wen L, Wu Q, Xiao X, Xu X, Yan J, Yang J, Yang M, Yang Y, Yin J, You C, Yu L, Yue X, Zhang F, Zhang J, Zhou Y, Zhu L, Zou Z, Baize N, Bombaron P, Chouaid C, Dansin E, Fournel P, Fraboulet G, Gervais R, Hominal S, Kahlout S, Lecaer H, Lena H, LeTreut J, Locher C, Molinier O, Monnet I, Oliviero G, Robinet G, Schoot R, Thomas P, Vergnènegre A, Berchem G, Rauh S, Al Husaini H, Aparisi F, Arriola E, Ballesteros I, Barneto I, Bernabé R, Blasco A, Bosch-Barrera J, Bover I, Calvo de Juan V, Camps C, Carcereny E, Catot S, Cobo M, De Las Peñas R, Dómine M, Felip E, García-Campelo MR, García-Girón C, García-Gómez R, Garcia-Sevila R, Garde J, Gasco A, Gil J, González-Larriba JL, Hernando-Polo S, Jantus E, Insa A, Isla D, Jiménez B, Lianes P, López-López R, López-Martín A, López-Vivanco G, Macias JA, Majem M, Marti-Ciriquian JL, Massuti B, Montoyo R, Morales-Espinosa D, Morán T, Moreno MA, Pallares C, Parera M, Pérez-Carrión R, Porta R, Provencio M, Reguart N, Rosell R, Rosillo F, Sala MA, Sanchez JM, Sullivan I, Terrasa J, Trigo JM, Valdivia J, Viñolas N, Viteri S, Botia-Castillo M, Mate JL, Perez-Cano M, Ramirez JL, Sanchez-Rodriguez B, Taron M, Tierno-Garcia M, Mijangos E, Ocaña J, Pereira E, Shao J, Sun X, O'Brate R. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. Ann Oncol 2014; 25:2147-2155. [PMID: 25164908 DOI: 10.1093/annonc/mdu389] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND In a Spanish Lung Cancer Group (SLCG) phase II trial, the combination of BRCA1 and receptor-associated protein 80 (RAP80) expression was significantly associated with outcome in Caucasian patients with nonsmall-cell lung cancer (NSCLC). The SLCG therefore undertook an industry-independent collaborative randomized phase III trial comparing nonselected cisplatin-based chemotherapy with therapy customized according to BRCA1/RAP80 expression. An analogous randomized phase II trial was carried out in China under the auspices of the SLCG to evaluate the effect of BRCA1/RAP80 expression in Asian patients. PATIENTS AND METHODS Eligibility criteria included stage IIIB-IV NSCLC and sufficient tumor specimen for molecular analysis. Randomization to the control or experimental arm was 1 : 1 in the SLCG trial and 1 : 3 in the Chinese trial. In both trials, patients in the control arm received docetaxel/cisplatin; in the experimental arm, patients with low RAP80 expression received gemcitabine/cisplatin, those with intermediate/high RAP80 expression and low/intermediate BRCA1 expression received docetaxel/cisplatin, and those with intermediate/high RAP80 expression and high BRCA1 expression received docetaxel alone. The primary end point was progression-free survival (PFS). RESULTS Two hundred and seventy-nine patients in the SLCG trial and 124 in the Chinese trial were assessable for PFS. PFS in the control and experimental arms in the SLCG trial was 5.49 and 4.38 months, respectively [log rank P = 0.07; hazard ratio (HR) 1.28; P = 0.03]. In the Chinese trial, PFS was 4.74 and 3.78 months, respectively (log rank P = 0.82; HR 0.95; P = 0.82). CONCLUSION Accrual was prematurely closed on the SLCG trial due to the absence of clinical benefit in the experimental over the control arm. However, the BREC studies provide proof of concept that an international, nonindustry, biomarker-directed trial is feasible. Thanks to the groundwork laid by these studies, we expect that ongoing further research on alternative biomarkers to elucidate DNA repair mechanisms will help define novel therapeutic approaches. TRIAL REGISTRATION NCT00617656/GECP-BREC and ChiCTR-TRC-12001860/BREC-CHINA.
Collapse
Affiliation(s)
- T Moran
- Catalan Institute of Oncology, Medical Oncology Service, Hospital Germans Trias i Pujol, Badalona, Spain
| | - J Wei
- The Comprehensive Cancer Centre, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
| | - M Cobo
- Medical Oncology Service, Hospital Carlos Haya, Malaga
| | - X Qian
- The Comprehensive Cancer Centre, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
| | - M Domine
- Medical Oncology Service, Fundacion Jimenez Diaz, Madrid
| | - Z Zou
- The Comprehensive Cancer Centre, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
| | - I Bover
- Medical Oncology Service, Hospital Son Llatzer, Palma de Mallorca
| | - L Wang
- The Comprehensive Cancer Centre, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
| | - M Provencio
- Medical Oncology Service, Hospital Puerta de Hierro, Madrid, Spain
| | - L Yu
- The Comprehensive Cancer Centre, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
| | - I Chaib
- Catalan Institute of Oncology, Medical Oncology Service, Hospital Germans Trias i Pujol, Badalona, Spain
| | - C You
- Department of Oncology, Suqian General Hospital, Suqian, China
| | - B Massuti
- Medical Oncology Service, Hospital General de Alicante, Alicante, Spain
| | - Y Song
- Department of Pneumology, Jinling Hospital, Nanjing, China
| | - A Vergnenegre
- Service de Pathologie Respiratoire et d'Allergologie, CHU Limoges, Limoges, France
| | - H Lu
- Department of Pneumology, Taizhou General Hospital, Taizhou, China
| | | | - W Hu
- The Comprehensive Cancer Centre, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
| | - G Robinet
- Service Pneumologie, CHU Brest, Brest, France
| | - J Yan
- The Comprehensive Cancer Centre, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
| | - A Insa
- Medical Oncology Service, Hospital Clinico de Valencia, Valencia, Spain
| | - X Xu
- Department of Pneumology, Northern Jiangsu People's Hospital, Yangzhou, China
| | - M Majem
- Medical Oncology Service, Hospital Sant Pau, Barcelona, Spain
| | - X Chen
- Department of Oncology, Huaian General Hospital, Huaian, China
| | - R de Las Peñas
- Medical Oncology Service, Hospital Provincial de Castellon, Castellon, Spain
| | - N Karachaliou
- Translational Research Unit, Dr Rosell Oncology Institute, Quiron-Dexeus University Hospital, Barcelona
| | - M A Sala
- Medical Oncology Service, Hospital de Basurto, Bilbao, Spain
| | - Q Wu
- Department of Oncology, Yixin General Hospital, Yixin, China
| | - D Isla
- Medical Oncology Service, Hospital Lozano Blesa, Zaragoza, Spain
| | - Y Zhou
- Department of Oncology, Yixin General Hospital, Yixin, China
| | - N Baize
- Department de Pneumologie, CHU Angers, Angers, France
| | - F Zhang
- Department of Oncology, Maanshan General Hospital, Maanshan, China
| | - J Garde
- Medical Oncology Service, Hospital Arnau de Vilanova, Valencia, Spain
| | - P Germonpre
- Department of Pulmonary Medicine, Antwerp University Hospital, Edegem, Belgium
| | - S Rauh
- Department of Internal Medicine and Oncology, Centre Hospitalier Emile Mayrisch, Luxembourg, Luxembourg
| | - H ALHusaini
- Oncology Center, King Faisal Cancer Center, Riyadh, Saudi Arabia
| | - M Sanchez-Ronco
- Department of Health and Medicosocial Sciences, University of Alcala, Madrid
| | | | - J J Sanchez
- Department of Preventive Medicine, Autonomous University of Madrid, Madrid
| | - C Camps
- Medical Oncology Service, Hospital General de Valencia, Valencia
| | - B Liu
- The Comprehensive Cancer Centre, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
| | - R Rosell
- Catalan Institute of Oncology, Cancer Biology and Precision Medicine Program, Hospital Germans Trias i Pujol, Badalona; MORe Foundation, Barcelona, Spain; Cancer Therapeutic Innovation Group, New York,USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012. [DOI: 78495111110.1016/s1470-2045(11)70393-x' target='_blank'>'"<>78495111110.1016/s1470-2045(11)70393-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [78495111110.1016/s1470-2045(11)70393-x','', 'Pierre Bombaron')">Reference Citation Analysis] [78495111110.1016/s1470-2045(11)70393-x', 13)">What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
78495111110.1016/s1470-2045(11)70393-x" />
|
14
|
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13:239-46. [PMID: 22285168 DOI: 10.1016/s1470-2045(11)70393-x] [Citation(s) in RCA: 4169] [Impact Index Per Article: 347.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
Abstract
BACKGROUND Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations. We aimed to assess the safety and efficacy of erlotinib compared with standard chemotherapy for first-line treatment of European patients with advanced EGFR-mutation positive NSCLC. METHODS We undertook the open-label, randomised phase 3 EURTAC trial at 42 hospitals in France, Italy, and Spain. Eligible participants were adults (> 18 years) with NSCLC and EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease (neoadjuvant or adjuvant chemotherapy ending ≥ 6 months before study entry was allowed). We randomly allocated participants (1:1) according to a computer-generated allocation schedule to receive oral erlotinib 150 mg per day or 3 week cycles of standard intravenous chemotherapy of cisplatin 75 mg/m(2) on day 1 plus docetaxel (75 mg/m(2) on day 1) or gemcitabine (1250 mg/m(2) on days 1 and 8). Carboplatin (AUC 6 with docetaxel 75 mg/m(2) or AUC 5 with gemcitabine 1000 mg/m(2)) was allowed in patients unable to have cisplatin. Patients were stratified by EGFR mutation type and Eastern Cooperative Oncology Group performance status (0 vs 1 vs 2). The primary endpoint was progression-free survival (PFS) in the intention-to-treat population. We assessed safety in all patients who received study drug (≥ 1 dose). This study is registered with ClinicalTrials.gov, number NCT00446225. FINDINGS Between Feb 15, 2007, and Jan 4, 2011, 174 patients with EGFR mutations were enrolled. One patient received treatment before randomisation and was thus withdrawn from the study; of the remaining patients, 86 were randomly assigned to receive erlotinib and 87 to receive standard chemotherapy. The preplanned interim analysis showed that the study met its primary endpoint; enrolment was halted, and full evaluation of the results was recommended. At data cutoff (Jan 26, 2011), median PFS was 9·7 months (95% CI 8·4-12·3) in the erlotinib group, compared with 5·2 months (4·5-5·8) in the standard chemotherapy group (hazard ratio 0·37, 95% CI 0·25-0·54; p < 0·0001). Main grade 3 or 4 toxicities were rash (11 [13%] of 84 patients given erlotinib vs none of 82 patients in the chemotherapy group), neutropenia (none vs 18 [22%]), anaemia (one [1%] vs three [4%]), and increased amino-transferase concentrations (two [2%] vs 0). Five (6%) patients on erlotinib had treatment-related severe adverse events compared with 16 patients (20%) on chemotherapy. One patient in the erlotinib group and two in the standard chemotherapy group died from treatment-related causes. INTERPRETATION Our findings strengthen the rationale for routine baseline tissue-based assessment of EGFR mutations in patients with NSCLC and for treatment of mutation-positive patients with EGFR tyrosine-kinase inhibitors. FUNDING Spanish Lung Cancer Group, Roche Farma, Hoffmann-La Roche, and Red Temática de Investigacion Cooperativa en Cancer.
Collapse
|
15
|
Grivaux M, Locher C, Bombaron P, Asselain B, Blanchon F, Coëtmeur D, Collon T, Dayen C, Debieuvre D, Goupil F, Le Treut J, Molinier O, Martin F, Zureik M. Étude KBP-2010-CPHG : description de 7414 nouveaux cas de cancer bronchopulmonaire primitif (CBP) pris en charge dans les hôpitaux généraux en 2010. Rev Mal Respir 2012. [DOI: 10.1016/j.rmr.2011.10.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
16
|
Grivaux M, Locher C, Bombaron P, Collon T, Coëtmeur D, Dayen C, Debieuvre D, Goupil F, Le Treut J, Martin F, Molinier O, Asselain B, Zureik M, Blanchon F. [Study KBP-2010-CPHG: inclusion of new cases of primary lung cancer diagnosed in general hospital pneumology departments between 1st January and 31 December 2010]. Rev Pneumol Clin 2010; 66:375-382. [PMID: 21167448 DOI: 10.1016/j.pneumo.2010.08.001] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/09/2010] [Accepted: 08/15/2010] [Indexed: 05/30/2023]
Abstract
INTRODUCTION The College of General Hospital Respiratory Physicians (CPHG) is following up the KBP-2000-CPHG study, performed ten years ago, with a new observational epidemiological study of primary lung cancer. PATIENTS AND METHODS The study includes all new cases of primary lung cancer diagnosed on histology or cytology between 1 January and 31 December 2010 and managed by one of the general hospital pneumology departments participating in the study. The primary objective is to estimate five-year mortality and to analyze risk factors. Secondary objectives are to describe the characteristics of this patient population and their management, and to estimate one, four and five-year survival rates. These data will be compared to those of the KBP-2000-CPHG study. The four-year prognosis score developed in 2000 will also be assessed in the new study. Data are collected by standardized questionnaire with exhaustiveness control. EXPECTED RESULTS One hundred and eight investigating centers have agreed to participate; 4000 to 5000 new cases of primary lung cancer should be collected and analyzed. CONCLUSION The study will describe the characteristics of patients presenting with primary lung cancer in the participating pneumology departments during the year 2010, and their diagnostic and therapeutic management, and assess changes over the last ten years.
Collapse
Affiliation(s)
- M Grivaux
- Service de pneumologie, centre hospitalier de Meaux, 6-8 rue Saint-Fiacre, BP 218, 77104 Meaux cedex, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Martzolff L, Bouhala M, Dukic R, Saraceni O, Wilhelm JM, Bombaron P, Kieffer P. Paralysie du nerf récurrent au cours d’une maladie de Lyme : à propos de deux observations. Rev Med Interne 2010; 31:229-31. [DOI: 10.1016/j.revmed.2009.07.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2009] [Revised: 07/05/2009] [Accepted: 07/08/2009] [Indexed: 10/19/2022]
|
18
|
LeCaer H, Barlesi F, Robinet G, Fournel P, Geriniere L, Bombaron P, Falchero L, Auliac JB, Crequit J, Chouaid C. An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study. Lung Cancer 2007; 57:72-8. [PMID: 17391803 DOI: 10.1016/j.lungcan.2007.02.012] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2006] [Revised: 02/13/2007] [Accepted: 02/14/2007] [Indexed: 12/27/2022]
Abstract
CONTEXT The objective of this study was to evaluate the feasibility and activity of weekly docetaxel monotherapy in frail elderly patients with advanced-stage non-small-cell lung cancer, selected on the basis of their precise age, general condition, and number of comorbid disorders (Charlson score). METHODS Analysis of the response rate, toxicity, quality of life, median survival and 1-year survival rates after 1-3 six-week cycles of docetaxel 30mg/m(2) weekly. RESULTS Fifty patients were enrolled and 42 were assessable. Five patients (10%, [3.7-22.6]) had objective responses, 14 (28%, [16.9-41.6]) had stable disease, and 23 (46%, [32.6-52.8]) progressed. The main grade 3-4 toxicity was fatigue (30%). Quality of life remained stable during treatment. The median survival time was 4.3 months, and the 1-year survival rate was 21.8%. CONCLUSION In frail elderly patients selected on the basis of their age, general condition and comorbidity, weekly docetaxel monotherapy has acceptable toxicity and does not negatively affect quality of life. In contrast, it has only moderate activity.
Collapse
Affiliation(s)
- Hervé LeCaer
- Service de Pneumologie, CH de Draguignan Route Montferrat, 83300 Draguignan, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Cortot AB, Gerinière L, Robinet G, Breton JL, Corre R, Falchero L, Berard H, Gimenez C, Chavaillon JM, Perol M, Bombaron P, Mercier C, Souquet PJ. Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study. Ann Oncol 2006; 17:1412-7. [PMID: 16790516 DOI: 10.1093/annonc/mdl146] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND Brain metastases (BM) considerably worsen the prognosis of non-small-cell lung cancer (NSCLC) patients. The usefulness and choice of chemotherapy remain uncertain in this indication since these patients are excluded from most clinical trials. We conducted a phase II study to determine the efficacy and tolerability of up-front chemotherapy with association of temozolomide and cisplatin in NSCLC patients with BM. PATIENTS AND METHODS Fifty NSCLC patients with BM received temozolomide (200 mg/m(2)/day for 5 days every 28 days) and cisplatin (75 mg/m(2) at day 1 of each cycle), up to six cycles, followed by whole brain radiotherapy (WBRT). An evaluation was carried out every two cycles and after WBRT. WBRT was performed earlier in case of progressive disease at any time or stable disease after cycle 4. RESULTS Eight objective responses were achieved (16%). Overall median survival was 5 months. Median time to progression was 2.3 months. Ten patients (20%) presented a grade 3/4 neutropenia and 11 patients (22%) presented a grade 3/4 thrombopenia. CONCLUSION This study demonstrates a lack of efficacy of up-front chemotherapy with association of temozolomide and cisplatin in these patients. Nevertheless, it supports the feasibility of chemotherapy before brain radiotherapy in NSCLC patients with BM.
Collapse
Affiliation(s)
- A B Cortot
- Service de Pneumologie, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Thomas P, Robinet G, Gouva S, Fournel P, Léna H, Le Caer H, Perol M, Berard H, Bombaron P, Vergnenegre A, Kleisbauer JP. Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer. Lung Cancer 2006; 51:105-14. [PMID: 16310886 DOI: 10.1016/j.lungcan.2005.10.004] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2005] [Revised: 09/19/2005] [Accepted: 10/03/2005] [Indexed: 11/17/2022]
Abstract
PURPOSE To evaluate the efficacy and safety of gemcitabine and carboplatin in the treatment of previously untreated patients with advanced non-small cell lung cancer (NSCLC). METHODS A randomized phase II study was conducted by the Groupe Français de Pneumo-Cancérologie (GFPC) in 15 centers. The patients were randomized in either arm A (GC): gemcitabine 1250 mg/m2 on days 1 and 8+carboplatin AUC 6 mg/(mLmin) on day 1; or in arm B (VP): vinorelbine 30 mg/m2 weekly+cisplatin 80 mg/m2 on day 1. Treatment cycles were repeated every 3 weeks. RESULTS A total of 100 patients were randomized with stage IV or stage III NSCLC with malignant pleural effusion: 51 patients in arm A and 49 patients in arm B. A total of 190 cycles were administered in the GC arm and 172 cycles in the VP arm, with a median of four cycles per patient in each arm. The dose intensity was 84.9% for gemcitabine, 99.8% for carboplatin, 97.7% for cisplatin and 67.7% for vinorelbine. The objective response rates were 19.6% (95% CI, 9.8-33.1) for GC and 29.2% (95% CI, 17.0-44.1) for VP in an ITT analysis. The response duration was 169 days in arm A and 226 days in arm B. The TTP was similar with 140 days (GC) and 148 days (VP), respectively. Overall survival rates were 334 days in the GC combination and 304 days in the VP combination. Overall, the treatment was safe and toxicities observed were different in each arm: neutropenia was the most common toxicity in the VP treatment, whereas thrombocytopenia was more frequent in the GC combination. Anemia was similar in both arms. Non-haematologic toxicity was mild. One toxic death in arm A and three toxic deaths in arm B were observed. CONCLUSION In terms of response rate, the gemcitabine-carboplatin combination was not efficient enough to allow further phase III study. Survival data are in the same range as the standard arm. This chemotherapy is feasible and may represent an alternative to a standard cisplatin-based regimen, allowing treatment in an outpatient setting.
Collapse
Affiliation(s)
- P Thomas
- Service d'Oncologie Respiratoire, Hôpital Sainte-Marguerite, 270 Bd Sainte-Marguerite, 13009 Marseille, and Service de Pneumologie, Hôpital Nord, Centre Hospitalier Universitaire de Saint-Etienne, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Le Caer H, Gimenez C, Chouaid C, Jullian H, Le Treut J, Bombaron P, Geriniere L, Hominal S, Dominique P, Auliac J. P-548 A multicenter phase II study of docetaxel/gemcitabine weekly inadvanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts): Preliminary results of the 02-02 Groupe Français de Pneumo-Cancérologie (GFPC) study. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)81041-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
22
|
Grivaux M, Breton JL, Bombaron P, Kuntz P, Lebas FX, Mehdaoui A, Herman D, David P, Berruchon J, Delclaux B, Zureik M, Blanchon F. Lung cancer among women in France. Lung Cancer 2004; 45:279-87. [PMID: 15301868 DOI: 10.1016/j.lungcan.2004.02.010] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2003] [Revised: 02/06/2004] [Accepted: 02/10/2004] [Indexed: 11/18/2022]
Abstract
As the incidence of primary lung cancer in women seems to be increasing in parallel with that of smoking, we conducted an exhaustive epidemiological study in 137 hospitals in 2000. We identified 904 women with proven primary lung cancer (mean age 63.9 years), many of whom have never smoked (32.3%), particularly in cases of adenocarcinoma (43.4%). Small cell cancer accounted for 16.1% of cases. Adenocarcinomas were the most frequent (45.3%) of the non-small cell lung cancer (NSCLC), followed by squamous cell (23.4%), large cell (11.6%) and bronchoalveolar (1.9%) carcinomas. About one third (32.2%) of NSCLC were stage III and 48.1% were stage IV. Over half of all adenocarcinomas were stage IV. According to multivariate analysis, adenocarcinoma is related to less smoking and younger age. In conclusion, many women affected by lung cancer have never smoked. Adenocarcinoma appears to be the most frequent form and more often at a metastatic stage.
Collapse
Affiliation(s)
- Michel Grivaux
- Department of Pneumology, Meaux Hospital, 6-8, rue Saint Fiacre, BP 218, 77108 Meaux cedex, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Lebitasy MP, Monnet I, Depierre A, Girard P, Berard H, Fournel P, Vaylet F, Rivière A, Bombaron P, Quoix E. Management of elderly lung cancer patients in France: A national prospective survey by the French Intergroup of thoracic Oncology (IFCT). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.8163] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. P. Lebitasy
- Service de Pneumologie Lyautey, Strasbourg, France; Centre Hospitalier Intercommunal, Creteil, France; Service de Pneumologie, Besancon, France; Institut Mutualiste Montsouris, Paris, France; Service de Pneumologie HIA Ste Anne, Toulon, France; CHU Service de Pneumologie, St Etienne, France; Service de Pneumologie HIA Percy, Clamart, France; Centre François Baclesse, Caen, France; Service de Pneumologie, Mulhouse, France
| | - I. Monnet
- Service de Pneumologie Lyautey, Strasbourg, France; Centre Hospitalier Intercommunal, Creteil, France; Service de Pneumologie, Besancon, France; Institut Mutualiste Montsouris, Paris, France; Service de Pneumologie HIA Ste Anne, Toulon, France; CHU Service de Pneumologie, St Etienne, France; Service de Pneumologie HIA Percy, Clamart, France; Centre François Baclesse, Caen, France; Service de Pneumologie, Mulhouse, France
| | - A. Depierre
- Service de Pneumologie Lyautey, Strasbourg, France; Centre Hospitalier Intercommunal, Creteil, France; Service de Pneumologie, Besancon, France; Institut Mutualiste Montsouris, Paris, France; Service de Pneumologie HIA Ste Anne, Toulon, France; CHU Service de Pneumologie, St Etienne, France; Service de Pneumologie HIA Percy, Clamart, France; Centre François Baclesse, Caen, France; Service de Pneumologie, Mulhouse, France
| | - P. Girard
- Service de Pneumologie Lyautey, Strasbourg, France; Centre Hospitalier Intercommunal, Creteil, France; Service de Pneumologie, Besancon, France; Institut Mutualiste Montsouris, Paris, France; Service de Pneumologie HIA Ste Anne, Toulon, France; CHU Service de Pneumologie, St Etienne, France; Service de Pneumologie HIA Percy, Clamart, France; Centre François Baclesse, Caen, France; Service de Pneumologie, Mulhouse, France
| | - H. Berard
- Service de Pneumologie Lyautey, Strasbourg, France; Centre Hospitalier Intercommunal, Creteil, France; Service de Pneumologie, Besancon, France; Institut Mutualiste Montsouris, Paris, France; Service de Pneumologie HIA Ste Anne, Toulon, France; CHU Service de Pneumologie, St Etienne, France; Service de Pneumologie HIA Percy, Clamart, France; Centre François Baclesse, Caen, France; Service de Pneumologie, Mulhouse, France
| | - P. Fournel
- Service de Pneumologie Lyautey, Strasbourg, France; Centre Hospitalier Intercommunal, Creteil, France; Service de Pneumologie, Besancon, France; Institut Mutualiste Montsouris, Paris, France; Service de Pneumologie HIA Ste Anne, Toulon, France; CHU Service de Pneumologie, St Etienne, France; Service de Pneumologie HIA Percy, Clamart, France; Centre François Baclesse, Caen, France; Service de Pneumologie, Mulhouse, France
| | - F. Vaylet
- Service de Pneumologie Lyautey, Strasbourg, France; Centre Hospitalier Intercommunal, Creteil, France; Service de Pneumologie, Besancon, France; Institut Mutualiste Montsouris, Paris, France; Service de Pneumologie HIA Ste Anne, Toulon, France; CHU Service de Pneumologie, St Etienne, France; Service de Pneumologie HIA Percy, Clamart, France; Centre François Baclesse, Caen, France; Service de Pneumologie, Mulhouse, France
| | - A. Rivière
- Service de Pneumologie Lyautey, Strasbourg, France; Centre Hospitalier Intercommunal, Creteil, France; Service de Pneumologie, Besancon, France; Institut Mutualiste Montsouris, Paris, France; Service de Pneumologie HIA Ste Anne, Toulon, France; CHU Service de Pneumologie, St Etienne, France; Service de Pneumologie HIA Percy, Clamart, France; Centre François Baclesse, Caen, France; Service de Pneumologie, Mulhouse, France
| | - P. Bombaron
- Service de Pneumologie Lyautey, Strasbourg, France; Centre Hospitalier Intercommunal, Creteil, France; Service de Pneumologie, Besancon, France; Institut Mutualiste Montsouris, Paris, France; Service de Pneumologie HIA Ste Anne, Toulon, France; CHU Service de Pneumologie, St Etienne, France; Service de Pneumologie HIA Percy, Clamart, France; Centre François Baclesse, Caen, France; Service de Pneumologie, Mulhouse, France
| | - E. Quoix
- Service de Pneumologie Lyautey, Strasbourg, France; Centre Hospitalier Intercommunal, Creteil, France; Service de Pneumologie, Besancon, France; Institut Mutualiste Montsouris, Paris, France; Service de Pneumologie HIA Ste Anne, Toulon, France; CHU Service de Pneumologie, St Etienne, France; Service de Pneumologie HIA Percy, Clamart, France; Centre François Baclesse, Caen, France; Service de Pneumologie, Mulhouse, France
| |
Collapse
|
24
|
Robinet G, Breton J, Lena H, Geriniere L, Gimenez C, Falchero L, Berard H, Bombaron P, Letreut J, Perol M, Souquet P. 42 Essai de phase II de l’association cisplatine-témozolomide dans les métastases cérébrales des cancers bronchiques non à petites cellules (CNPC). Etude glot-GFPC. Rev Mal Respir 2004. [DOI: 10.1016/s0761-8425(04)71668-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
25
|
Blanchon F, Breton JL, Grivaux M, Bombaron P, Kuntz P, Lebas FX, Medahoul A, Herman D, David P, Berruchon J. O-83 Lung cancer among women: epidemiological data about 5667 new diagnosed cases in 2000 in France. Lung Cancer 2003. [DOI: 10.1016/s0169-5002(03)91741-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
26
|
Larive S, Bombaron P, Riou R, Fournel P, Perol M, Lena H, Dussopt C, Philip-Joet F, Touraine F, Lecaer H, Souquet PJ. Carboplatin-etoposide combination in small cell lung cancer patients older than 70 years: a phase II trial. Lung Cancer 2002; 35:1-7. [PMID: 11750705 DOI: 10.1016/s0169-5002(01)00288-4] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND No standard treatment is defined for elderly patients with small cell lung cancer (SCLC). Carboplatin and etoposide are highly active agents against SCLC. In this study, we evaluated the activity and toxicity of a combination of these two agents. PATIENTS AND METHODS Thirty-four untreated patients with limited or extensive SCLC and median age of 73.9 years entered the study. Chemotherapy consisted of carboplatin i.v. on day 1 (AUC 5 using Calvert's formula) and etoposide 100 mg/m(2) given orally on days 1-5, every 4 weeks, and thoracic irradiation was given to limited disease patients after chemotherapy. RESULTS The overall response rates was 59% (95% CI: 43-76). The median survival for all patients was 37 weeks (range 3-76 weeks). The toxicity was mainly haematological with grade 3-4 neutropenia in 59% of courses, febrile neutropenia in 15% of courses, and toxic death in 9% of patients. CONCLUSION The results of this regimen are disappointing with worse response and survival, and more haematological toxicity than expected and previously reported, despite the use of Calvert's formula. Possible explanations are the use of etoposide per os rather than i.v., the frequent comorbidities of older patients and the inclusion of patients with poor prognosis factors.
Collapse
Affiliation(s)
- S Larive
- Service de Pneumologie, Centre Hospitalier Lyon Sud, 69495 Cedex, Pierre Bénite, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Vergnenègre A, Molinier L, Chouaïd C, Schuller-Lebeau M, Gouttenoire F, Brobeck C, Brevelet C, Bachaud M, Bombaron P, Douillard J, Monnier A, Poirier R, Quoix E, Robinet G, Urban T. Practice of lung cancer health care in France. Lung Cancer 2000. [DOI: 10.1016/s0169-5002(00)80783-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
28
|
Benchalal M, Salze P, Bombaron P, Bourderont D, Neidhardt AC, Maitre AM, Pignol JP, Lambert J, Baumann J, Sizaret O, Newinger G, Noirclerc M, Sabountchi M, Zipper JM, Prevot G. [Concurrent split-course chemotherapy and radiotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a Phase II study]. Cancer Radiother 1999; 3:453-60. [PMID: 10630157 DOI: 10.1016/s1278-3218(00)88251-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
PURPOSE We initiated at Hospital de Mulhouse a prospective phase II study to assess a split-course concurrent radiochemotherapy in locally advanced non-small cell lung cancer. MATERIALS AND METHODS From March 1996 to December 1997, 28 patients were included in our study. All patients had a stage III cancer. The chemotherapy scheduled included vinorelbine (20 mg/m2/d, d1 and d5), cisplatin (20 mg/m2/d, from d1 to d5), and 5-Fluorouracil (350 mg/m2/d, from d1 to d5 by continuous infusion). The planned irradiation dose was 12.5 Gy per week with one daily fraction of 2.5 Gy from d1 to d5. Cycles were repeated every four weeks, for four cycles (50 Gy). Patients with a partial or complete response were proposed a fifth cycle. RESULTS Of the 28 patients of the study, only 27 were analysed; one patient had a metastatic disease at diagnosis. Major hematologic toxicity occurred in 26% of the patients. One to five cycles of chemoradiotherapy were administrated per patient (median: four). Four patients had received fewer than three cycles and their responses were not assessable. Of the 23 patients assessed, 12 responses (52%) were observed, three CR (13%) and nine PR (39%). Median follow-up was 14 months, and median survival 13.5 months. One- and two-year survival rates were respectively 63% and 14%. Local control rates was 11%, and 44% of the patients had a metastatic evolution. CONCLUSION Very preliminary results of this phase II study are disappointing, and quite inferior to the published results using chemoradiotherapy with conventional or hyperfractionated radiotherapy. Hematologic toxicity is restrictive. This type of chemoradiotherapy cannot be recommended.
Collapse
Affiliation(s)
- M Benchalal
- Service d'oncoradiothérapie de Mulhouse, hôpital du Hasenrain, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Durupt S, Bombaron P, Gerinière L, Isaac-Pinet S, Souquet PJ, Bernard JP. [Late-onset pleurisy: a rare complication of thoracic radiotherapy]. Presse Med 1998; 27:762. [PMID: 9767900] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/09/2023] Open
|
30
|
Brunel-Crova J, Guibert B, Mulsant P, Souquet PJ, Gérinière L, Bombaron P, Bernard JP. [Long-term outcome of 72 patients surgically treated for stage II non-small cell bronchial cancer, between 1982 and 1989]. Rev Mal Respir 1997; 14:457-63. [PMID: 9496604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
We report a 72 patients trial, who had surgical treatments for non small cell lung cancer, stage II (T1N1, T2N1). In our retrospective study, the overall 5-years survival is 44%, with a 24-month median survival. 45% of the patients have recurrence mainly due to distant metastasis. State II appears to be an heterogeneous group. As shown in other studies, the presence of hilar nodes (N1H) seems to be linked with a pejorative outcome. In our series, the survival associated with Lobar N1 (N1L) disease is the same as the survival of Hilar N1 disease, but the initial sites of recurrence differ. The interest of a postchirurgical treatment is controversial. The postoperative radiotherapy reduces the local recurrence without increasing the survival. The chemotherapy treatment is debatable and several studies are under way. We reviewed the different causes of death. The appearance of second cancer in the cured patients is very frequent.
Collapse
Affiliation(s)
- J Brunel-Crova
- Service de Pneumologie, Centre Hospitalo-Universitaire Lyon-Sud, Pierre-Bénite
| | | | | | | | | | | | | |
Collapse
|
31
|
Khouatra C, Honnorat J, Bombaron P, Gerinière L, Pinede L, Gonnaud PM, Souquet PJ, Pasquier J, Bernard JP. [Paraneoplastic intestinal pseudo-occlusion and sensory neuronopathy disclosing small-cell bronchial cancer]. Rev Med Interne 1997; 18:652-6. [PMID: 9365741 DOI: 10.1016/s0248-8663(97)82468-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
This report describes a case of paraneoplastic neurological syndrome associating a subacute sensory neuronopathy and an intestinal pseudo-obstruction in a 64-year old man with a small cell lung cancer. Various paraneoplastic neurological syndromes have been described in association with small cell lung cancer. In our patient anti-Hu antibodies were identified by indirect immunohistochemistry and western-blot analysis. This antibody constitutes an informative tool in assessing the paraneoplastic origin of neurologic symptoms when the etiological inquiry is negative. Its positivity is important in promoting the search for an underlying malignancy and should lead to repeat investigations if the first investigations are normal.
Collapse
Affiliation(s)
- C Khouatra
- Service de pneumologie, hôpital Lyon-Sud, France
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Pérol M, Souquet P, Riou R, Fournel P, Dussopt C, Vuillermoz S, Bombaron P, Tete L, Pellae-Cosset B. 128 Preliminary results of a phase II study with Taxol® (paclitaxel) and cisplatin in advanced non-small cell lung cancer (NSCLC). Lung Cancer 1997. [DOI: 10.1016/s0169-5002(97)89407-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
33
|
Souquet P, Bombaron P, Brunel-Crova J, Bernard J. 82 Treatment of advanced and disseminated non small lung cancer (NSCLC) in elderly patients: Results of the MIC regimen. Lung Cancer 1997. [DOI: 10.1016/s0169-5002(97)89361-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
34
|
Bombaron P, Lemaire C, Souquet PJ, Gériniere L, Bourlon D, Guibert B, Voloch A, Bernard JP. [Endovascular closure of a foramen ovale after a right pneumonectomy]. Rev Mal Respir 1997; 14:133-5. [PMID: 9198836] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
We report the case of a patient, 62-year-old, with a non small cell lung cancer treated by right pneumonectomy followed by chemo and radiotherapy. After surgery appeared a refractory hypoxemia increasing with supine position. Cardiac catheterism showed a right left shunt by reopening of the "foramen ovale". We have performed foramen's occlusion by endovascular method with prothetic material with good result until the death, 14 months later, by neoplasic evolution.
Collapse
Affiliation(s)
- P Bombaron
- Service de Pneumologie, Centre Hospitalier Lyon-Sud, Pierre Bénite
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Ligneau B, Freyer G, Giraud S, Isaac S, Bombaron P, Espinouse D, Plauchu H, Fischer G, Gérard JP, Lenoir G, Trillet-Lenoir V. [Neurosarcoma associated with neurofibromatosis 1. Apropos of a case and review of the literature]. Presse Med 1997; 26:458-63. [PMID: 9137367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND Type 1 neurofibromatosis considerably increases the risk of cancer development, particularly neurosarcoma. We report a case in a patient with chemosensitive metastatic neurosarcoma. CASE REPORT A young female patient with familial type 1 neurofibromatosis developed pleural metastasis of a neurosarcoma located on the arm. This tumor was initially highly sensitive to chemotherapy, but relapse occurred. DISCUSSION Follow-up in the order members of the family was particularly difficult to organize. One sister developed cerebral astrocytoma. Neurosarcomas develop earlier in patients with type 1 neurofibromatosis, worsening prognosis. We suggest a prospective and structured registration of such cases using a network of clinicians and pathologists in order to improve management schemes.
Collapse
Affiliation(s)
- B Ligneau
- Service de Radiothérapie-Oncologie, Centre Hospitalier Lyon-Sud, Pierre-Bénite
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Kolber C, Souquet PJ, Gérinière L, Bombaron P, Mulsant P, Guibert B, Pinet-Isaac S, Bernard JP. [Spontaneous hydro-pneumothorax disclosing malignant mesothelioma. Apropos of 2 cases]. Rev Pneumol Clin 1996; 52:42-44. [PMID: 8731757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
We report the cases of two males who presented with spontaneous complete unilateral pneumothorax with ipisilateral liquid effusion. Neither had a history of previous respiratory disease. In both cases chest tube drainage resulted in recurrence of pneumothorax with chronic illness requiring surgical exploration. The surgery revealed a malignant pleural mesothelioma by histological examination. Thus, spontaneous pneumothorax, particularly with abondant effusion can be a revealing symptom of malignant pleural mesothelioma.
Collapse
Affiliation(s)
- C Kolber
- Service de Pneumologie, Centre Hospitalier Lyon Sud, Pierre Bénite
| | | | | | | | | | | | | | | |
Collapse
|